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1. INTRODUCTION 
When someone mention the eye to a professional in 
this field, the first thing that comes to mind is vision, and 
ocular pathologies which can lead to blindness. All the 
possible ocular diseases starting from the tear-film until 
the retina, could result in either reversible or irreversible 
blindness. However, the ocular organ exceeds this very 
important function, and it is rather a window for both out- 
and inside of the body. It is the organ which permits us to 
capture the daylight and all the information about the time 
of the day, and it is the first vehicle for photo-entrainment.  
In order to accomplish the function of photo-
entrainment, the ocular organ contains a small number of 
cells laying in the inner retina, which comprise a 
photopigment named melanopsin (1). This photopigment 
is responsible of capturing light and passing its signals 
through a series of chemical reactions to several brain 
regions, until it reaches the pineal gland, where it 
suppresses melatonin synthesis (2).  
With modern life, and the use of artificial light instead 
of depending on daylight, a serious debate was generated 
regarding the risk of light pollution. Melanopsin 
containing retinal ganglion cells receives confusing signals 
and it is activated when light is switched on at night; hence 
disrupting the circadian rhythm and leading to serious 
health issues as a consequence of suppressing melatonin 
synthesis (3). 
Melatonin (N-acetyl-5-methoxytryptamine) is a 
neurohormone classically known to be produced by the 
pineal gland (4). This hormone is considered the chemical 
expression of darkness, because of its role in regulating the 
circadian rhythm. Melatonin levels raise during the night 
and its levels are lower at daytime, hence, it is the natural 
sleep aid our body has (5). However, from the moment this 
hormone was discovered and characterized, numerous 
researchers investigated it, and they detected its presence 
not only by the blood stream, but also because it is 
synthesized in several organs and cells (6).  
ABSTRACT: Melatonin is a neurohormone 
synthesized in several ocular structures apart from its 
original source, the pineal gland. It is of great 
importance in several functions such as maintaining a 
healthy values of intraocular pressure. Moreover, it 
decreases intraocular pressure in the case of glaucoma. 
This nuerohormone is controlled by the activation of a 
photopigment responible for non-image forming tasks in 
the eye, this photopigment is Melanopsin, present in a 
subclass of retinal ganglion cells, and very recently, it 
was discovered in different ocular structures. When 
Melanopsin is activated by the short wavelength 
component of light, it supresses Melatonin synthesis. 
This action is controlled mainly by light could affect 
several functions including the regulation of intraocular 
pressure. In this sense, the present work highlights the 
history and importance of the relationship between both 
Melatonin and Melanopsin to maintain a healthy ocular 
homeostasis. 
 
RESUMEN: La Melatonina es una neurohormona 
sintetizada en varias estructuras oculares, aparte de su 
fuente original, la glándula pineal. Es de gran 
importancia por varias funciones, como el 
mantenimiento de valores saludables de presión 
intraocular. Además, disminuye la presión intraocular en 
el caso de glaucoma. Esta nuerohormona se controla 
mediante la activación de un fotopigmento responsable 
de las tareas no relacionada con la formación de 
imágenes en el ojo, este fotopigmento es la 
Melanopsina, presente en una subclase de células 
ganglionares de la retina y, muy recientemente, se 
descubrió en diferentes estructuras oculares. Cuando la 
melanopsina se activa por el componente de longitud de 
onda corta de la luz, suprime la síntesis de melatonina. 
Esta acción está controlada principalmente por la luz 
que podría afectar varias funciones, incluida la 
regulación de la presión intraocular. En este sentido, el 
presente trabajo destaca la historia y la importancia de la 
relación entre la melatonina y la melanopsina para 
mantener una homeostasis ocular saludable. 
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Several studies indicated the pharmacological effect of 
melatonin in the eye, moreover, the eye is a very special 
organ since it synthesizes this hormone and comprises its 
local machinery giving that several ocular structures are 
able to produce it. For instance, melatonin synthesizing 
enzymes were found first in the retina (7), then it was 
shown to be present in the iris, ciliary body, crystalline 
lens, and the harderian gland (8-10). Furthermore, studies 
confirmed its multitasking characteristics, exceeding the 
classical and once thought to be the only function of 
regulating the circadian rhythm (11).  
An interesting observation about melatonin and the 
physiology of the eye is the synchronization between 
melatonin levels and the intraocular pressure, where the 
later reaches its lowest levels at night while melatonin is at 
the highest (12, 13). Intraocular pressure is one of main 
factors in maintaining our ocular system healthy, since its 
elevation could lead to the second leading cause of 
blindness worldwide, glaucoma disease (14). 
Glaucoma is defined as a heterogenous group of 
progressive disorders characterized by optic neuropathy 
and retinal ganglion cell death (15). Many risk factors are 
involved in the development of this disease, such as the 
age, gender, genetics, intraocular pressure (IOP), and 
ethnicity. For instance, glaucoma cases accounts 8% of all 
blindness worldwide, but this percentage raise to 15% in 
African population (16). Glaucoma lacks primary 
symptoms and it leads gradually to a loss of the peripheral 
vision, as it is an under-diagnosed disease (17). In all the 
cases, intraocular pressure is the only risk factor which can 
be controlled in order to slow the progression of glaucoma. 
A variety of glaucoma medication are currently in use, and 
all of them function in order to keep IOP within healthy 
and normal limits (18). 
In the current review, light will be shed on melatonin in 
the eye with a special focus on glaucoma disease. Also, 
melanopsin role in regulating melatonin levels within the 
eye and its signalling pathways will be discussed. 
2.  MELATONIN HISTORY AND SYNTHESIS 
The history of melatonin goes back to many cultures 
and ages, by the reason of the pineal gland´s shape and 
location, and before being conscious about the 
neurohormone itself. For instance, in the greek culture, the 
pineal gland was given this name because it is shaped 
similar to the pine nut (19), and in the pharaonic Egypt, the 
pineal was considered the eye of Horus. Another 
speculation by the Hindu, describing the pineal gland as 
the third eye for spiritual enlightenment (20). However, 
one of the most remarkable historical definition of this 
curious gland was by the philosopher Descartes (1594–
1650), where he described the pineal gland as the seat of 
the soul and the region where our thoughts were formed 
(21).  
The pineal gland gained its importance through history, 
until 1958, when the dermatologist Aaron Lerner was 
looking for a cure for vitiligo, and he discovered the 
hormone secreted by this gland, melatonin (4). Therefore, 
this hormone was given the name melatonin as “mela” 
from melanin and “toni” from serotonin (4). 
Melatonin is first synthesized from tryptophan which is 
converted into serotonin (22). Certain amount of this 
hormone goes through acetylation by the first enzyme in 
melatonin synthesis, arylalkymine N-acetyltransferase 
(AANAT), to get N-acetylserotonin (NAS), which in turn 
is converted to melatonin with the help of the last enzyme 
involved in this process, hydroxyindole O-
methyltransferase (HIOMT), which catalyses the O-
methylation of NAS by S-adenosyl methionine to form 
melatonin (Fig.1) (23). Several studies haves indicated the 
importance of AANAT enzyme in the process of 
melatonin synthesis, and it is named the Timezyme, since 
its activity increases up to 100-fold at night, thus it is 
considered a key in regulating melatonin levels (24, 25).  
As commented in the introduction, melatonin was 
found to be produced by several ocular structures. But 
more importantly, in 1984 the synthesis of melatonin in the 
eye has gained additional interest after some experiments 
done in white leghorn cockerels, when Rohde and 
collaborators performed a pinealectomy procedure and 
then measured melatonin in several structures in the eye. 
Two important discoveries were made from this work, 
first, melatonin was measured in the retina, iris, and ciliary 
body resulted similar to the control. And second, 
melatonin concentration in the studied structures followed 
the same pattern as the pineal gland, raising during the 
night and decreasing at daylight (26).  
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Figure 1.  Diagramatic resprestentation of melatonin synthesis in the pineal gland. Starting from tryptophan in the blood stream, which is 
converted into serotonin.  The rise in AANAT activity results in an increase in the intracellular concentration of N-acetylserotonin which 
is further converted to melatonin by hydroxyindole-O-methyltransferase (modified from Klein, 1974). AANAT, arylalkylamine N-
acetyltransferase; AC, adenylate cyclase; HIOMT, hydroxyindole-O-methyltransferase; cAMP, cyclic adenosine monophosphate; CREB, 
cAMP response element-binding protein;NAS, N-acetyl 5-methoxytryptamine; NE, norepinephrine; PKA, protein kinase A. 
2.1. Melatonin receptors and functions 
Melatonin has the ability to function through its 
receptors, but also it have direct actions as a free radical 
scavenger. Melatonin have two cloned and characterized 
membrane receptors in mammals, MT1 and MT2. A 
putative MT3 was suggested by several authors, and in 
some cases it was claimed to belong to the quinone 
reductase family, specifically, quinone reductase 2 
(NQO2) (27, 28), although in other studies using different 
species through silencing this enzyme, melatonin still had 
functional properties (29).  
Melatonin receptors signalling pathways were 
extensively studied. In a canonical way, MT1 and MT2 
stimulation would lead to adenylate cyclase (AC) 
inactivation in a Gαi subunit process of the G protein 
coupled to the membrane receptor (30). When AC is 
inactivated, it would lead to a decrease in intracellular 
cAMP concentration, and finally a decrease in activated 
protein kinase A (PKA). The action of these receptors has 
been shown to inhibit forskolin-induced cAMP formation 
(31). However, melatonin receptors are also able to couple 
to different subtypes of G protein (32). Therefore the 
mentioned classical signal transduction is not the case in 
all cells and models, melatonin receptors activation also 
could lead to different intracellular signalling. For 
instance, some studies showed that MT1 receptor activation 
would activate phospholipase C-α (PLC-α) pathway (33); 
While MT2 receptor, in addition to classical inhibition of 
AC, has been described in inhibition processes of the 
enzyme guanylate cyclase (GC) (Fig. 2) (34). 
Hanan Awad Alkozi 
@Real Academia Nacional de Farmacia. Spain 52 
 
Figure 2.  Scheme showing membrane signalling by melatonin receptors MT1 and MT2, both G-protein coupled receptors. On the right is 
shown the interaction of Gi with adenyl cyclase (AC) to decrease cAMP levels and therefore cyclic AMP-dependent protein kinase 
activity (PKA). On the left is shown the interaction of Gq with phospholipase C (PLC) leading to the cleavage of phosphatidyl inositol 
diphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). These second messengers stimulate increased intracellular 
Ca2+ and protein kinase C (PKC), respectively. The downstream effects of these events at the membrane vary with cell type. 
2.2. Melatonin and glaucoma 
One of the most important risk factors for developing 
glaucoma disease in elevated intraocular pressure. 
Intraocular pressure consists of an equilibrium between the 
formation of the aqueous humor in the ciliary process and 
its drainage by the trabecular meshwork and the to some 
extent, the uveoscleral pathway (35, 36).  
The aqueous humor composed mainly of water and 
electrolytes to complete one of its functions apart from 
regulating IOP, to provide nutrients to the avascular 
structures bathe in it (37). Aqueous humor also contains 
melatonin, which also plays an important role in regulating 
IOP. Melatonin content in the aqueous humor originates 
from both the ciliary processes and the crystalline lens. In 
this sense, both exogenous and endogenous melatonin has 
been extensively investigated.  
Before coming into the interesting relationship between 
melatonin and melanopsin, it is worthy to explain the role 
melatonin have over IOP when applied or consumed 
exogenously. Melatonin consumption prior to cataract 
surgery showed a positive effect on the post-operative 
outcome and it reduced IOP (38). Moreover, melatonin 
and its analogue agomelatine showed an ocular 
hypotensive effect when applied topically to a 
normotensive and hypertensive model of New Zealand 
white rabbits (39) as well as in a glaucomatous animal 
model (40), same effect observed after oral consumption 
of agomelatine in human glaucoma patients (41). This 
effect of reducing IOP is mediated by melatonin receptors, 
since it triggers cAMP production and consequently 
inhibits chloride efflux in the ciliary processes, hence 
reduces aqueous humor production (42). Different studies 
used mice lacking melatonin receptor 1 showed that they 
suffered from elevated intraocular pressure and retinal 
ganglion cells death, both signs for developing glaucoma 
(43). Beside that effect, melatonin is known also as a free 
radical scavenger, it functions as an oxidative stress and it 
was shown to have a protective effect against retinal cells 
death by reducing the damage  produced by oxidative 
stress (44, 45). 
All of the mentioned studies used melatonin as an 
external pharmacological agent, however, melatonin 
content in the aqueous humor without any exogenous 
addition is not equal among all subjects. Analysis showed 
that certain conditions could lead to changes in melatonin 
levels in the aqueous humor. For instance, patients with 
elevated intraocular pressure have higher levels of 
melatonin in the aqueous humor. These results are in 
parallel to the analysis of melatonin levels in a mice model 
of glaucoma, both before and after developing the disease, 
and in comparison to the control healthy mice (46). These 
results were not only observed in the aqueous humor, but 
also seen in the serum melatonin level, were glaucoma 
patients had a significant increment of melatonin in blood 
compared to healthy patients (47). Human donor eyes were 
examined by immunohystochemistry assay against 
melatonin synthesizing enzyme AANAT, in both 
glaucomatous donors and healthy eyes, demonstrated an 
increased staining of AANAT in the ciliary body of 
glaucoma donors (48). In order to investigate these results, 
in vitro studies took place using immortalized human non-
pigmented ciliary body epithelial cells. To mimic the 
elevation of intraocular pressure, a vanilloid channel 
belonging to to the superfamily of TRPs present in these 
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cells, the TRPV4 channel was stimulated  since this 
protein is sensitive to mechanical pressure. The activation 
of this channel leaded to and increment of both melatonin 
levels extracellularly and an increase in the expression of 
the protein AANAT (48, 49). Other studies showed that 
the activation of this channel has a short term effect when 
activated, similar to a sudden increase of IOP, where it 
phosphorylate the enzyme AANAT, hence protecting it 
from degradation and leading to an increment of melatonin 
(50, 51). TRPV4 was silenced in the non-pigmented ciliary 
body epithelial cells to confirm the effect of melatonin 
increment, confirming the importance of this channel in 
regulating melatonin synthesis in the ciliary processes 
(52). This difference in melatonin levels in the aqueous 
humor was also reported for other diseases. A study 
analyzing melatonin levels in patients with proliferative 
diabetic retinopathy showed that those patients had a 
significant increase of melatonin in the aqueous humor 
compared to healthy subjects, and interestingly, this 
increment was not seen in serum samples taken from the 
same patients. This indicates that melatonin synthesis is 
increased in the eye only and its origin is not the 
circulating melatonin from the pineal gland (53). In fact, in 
a different study, melatonin decreased in blood serum of 
patients with type 2 diabetes with cardiac autonomic 
neuropathy (54), also urinary 6-sulfatoxymelatonin level in 
were found lower in patients with diabetic retinopathy with 
type 2 diabetes (55). 
All the mentioned studies are evidence of a possible 
melatonin modification or changes in the eye due to ocular 
diseases. However, a different perspective of melatonin 
regulation has rose due to a public serious issue; light 
pollution. Light at night is currently associated to several 
pathologies, and it is considered as a possible risk factor to 
develop many diseases, starting from obesity to a more 
serious pathologies such as cancer (56, 57). Light can 
disrupt the circadian rhythm and when it activates the non-
image forming photoreceptor situated in a small number of 
the retinal ganglion cells, melanopsin: It directly projects 
its signals to the pineal gland to shut-off melatonin 
synthesis, and it is associated directly or indirectly to a 
wide range of pathologies (58). 
3.  MELANOPSIN, THE HIDDEN RECEPTOR 
IN OUR EYES 
In the 1920s, a Harvard university graduate student, 
Clyde Keeler, discovered that blind mice due to rod and 
cone dystrophy, can still respond to ambient light by pupil 
constriction, and moreover, they conserved their ability for 
photo-entrainment (59). This was the first evidence of the 
presence of a different photoreceptor in the eye, however, 
since the retina is an extensively studied tissue, with all its 
layers, rods and cones were the only photoreceptors 
recognized by scientists for decades after Keeler´s 
observation. Nonetheless, all posterior studies confirmed 
that the eyes are essential as the primary source of light 
information for photo-entrainment, and eye loss in 
mammals abolishes this characteristic (60).  
Decades after Keeler´s discovery, in 2000, the scientist 
Provencio identified a small subclass of retinal ganglion 
cells which are photosensitive. This is because they 
contain a photopigment, melanopsin, sensitive to short 
wave length content of light (corresponding to blue light) 
(1). In fact, this photoreceptor was identified earlier in 
dermal melanophores, eye, and the brain of Xenopus 
laevis, but it was not found in extra-ocular regions in 
mammals (61). This discovery explained the reason why 
rodless and coneless eyes can still react to light.  
Interestingly, this photopigment have different 
characteristics than ones found in mammals. For instance, 
it presents greater homology to invertebrate opsin than 
those of vertebrate; melanopsin in mammals belongs to the 
rhabdomeric receptors unlike the ciliary receptors in rods 
and cones (62). Moreover, this photoreceptor depolarize in 
reaction to light, whereas rods and cone hyperpolarize. 
Moreover studies using pharmacological approaches 
suggested the biochemical phototransduction cascade to be 
similar to invertebrate rhabdomeric photoreceptors acting 
through Gq protein coupled opsin (63). After light 
stimulation, the photopigment of the intrinsically 
photosensitive retinal ganglion cells  (ipRGC) triggers 
signalling, presumably, through Gq/11-class G-
superfamily, which in turn activates a phospholipase C 
(PLC) (Fig. 3), provoking the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) in the 
membrane generating inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG) and the later increase in cytoplasmic 
Ca2+ and ultimately causing membrane depolarization. 
Furthermore, the participation of TRP and TRPL channels, 
the Ca2+-permeable light-sensitive channels, made clear 
since treatments with a Ca2+ chelator or a TRP channel 
blocker were able to reduce the light effect. Treating 
chicken primary  retinal ganglion cells (RGCs) cultures 
with PLC inhibitors abolished the light-suppressive effect 
on 3H-melatonin synthesis. These findings demonstrated 
the chemical components of the phototransduction cascade 
operating in vertebrate embryonic RGCs is involving a 
Gq-protein (64-66). 
When light reaches the inner retina and activate 
melanopsin containing ganglion cells, signals passes to 
different regions than the image forming pathway. They 
travel from the retina through the retinohypothalamic tract 
to the suprachiasmatic nucleus (SCN) and to the cervical 
superior ganglion and the pineal gland where light signals 
suppresses melatonin synthesis (Fig. 3) (67).  
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Figure 3.  Scheme of melanopsin pathway through retinal iRGCs to the suprachiasmatic nucleus for photoentrainment, reaching the 
paraventricular nucleus where it participate in pupillary light reflex. Finally signals reachs the pineal gland where melatonin synthesis is 
inhibited/activated by the intracellular pathway shown at the bottom of the photo. 
It is fascinating to think that the eye has much more 
functions other than image forming vision, and it 
participates in several physiological roles. In fact, being 
the first vehicle in regulating the circadian rhythm is of 
great importance since numerous biological activities 
follows a circadian manner (68). For instance, several 
evidence showed that fully blind humans with no light 
perception suffers from desynchronized circadian 
processes due to a lack of light input. This leaded to 
alteration of the pattern of alertness, mood, performance, 
alteration of core body temperature; which interferes with 
their social and professional lives even more seriously than 
the fact of being blind (67, 69). 
Very recently, melanopsin was detected in other ocular 
structures than the retina, it was found to be present in the 
crystalline lens as well as in the cornea (70, 71). 
Experiments showed that human epithelial crystalline lens 
reacts differently under light and darkness conditions, 
melatonin synthesizing enzyme AANAT as well as 
melatonin levels significantly increased when cells were 
submitted to total darkness compared to white light. 
Moreover, experiments done under different wave lengths 
showed that melatonin was suppressed in response to blue 
light, corresponding to an action mediated by melanopsin. 
This action was through phospholipase C (PLC) pathway, 
similar to melanopsin containing retinal ganglion cells 
(70). In the cornea, melanopsin expression was detected in 
the epithelium and near the endothelial surface. 
Surprisingly, experiments showed no light response in the 
mentioned study, suggesting a different sensory role for 
melanopsin in the cornea (71). Although the trigeminal 
ganglia in the source of most corneal nerve fibers, a 
different study showed that melanopsin is also expressed 
in the trigeminal ganglion neurons, and that it responded to 
light. This is specially interesting since these neurons are a 
classic pain sensory cells and the ability for light to cause 
pain is paradoxical, besides the fact that fiber endings in 
the cornea are specialized to respond to pressure, 
temperature, and caspaicin. All these findings together 
opens a new possible role for melanopsin in the cornea 
(72). 
3.1. The impact of melanopsin activation over melatonin 
synthesis: timing is everything 
One of the most fascinating facts about melanopsin is 
its unconscious response to light. Light is an ancient 
prehistorical phenomena which exists before any living 
being. Throughout the history, sun light have been a 
subject of amusement. In numerous cultures and societies 
sun light was considered as a source of life and 
nourishment, for example, ancient Egyptians were the first 
to report beneficial properties from sun exposure 6000 
years ago was reported. The Chinese introduced the art of 
morning sun gaze, and exercises such as yoga or tai chi has 
strong ties to sunlight (73). These potential benefits of sun 
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exposure were translated to the western world during the 
18th century, when light therapy was introduced for lupus 
vulgaris treatment; a discovery by Niels Finsen (1860-
1904) who was awarded the Nobel Prize in Medicine and 
Physiology (74, 75). 
Apart from sunlight, humans have come up with 
numerous ways to create artificial light along the history. 
From around 500,000 years ago, evidence showed that 
Homo erectus started to use fire light in caves. In Greece, 
bronze lamps were used around 700 B.C (76). Until the 
nineteenth century, the commonly used artificial light was 
the wax candle, which in comparison to the current 
lighting, wax candles had very low intensities and low 
color temperature; hence they produced a very little effect 
on the circadian system (77). In 1801, Humphrey Davey 
discovered the incandescence of an energized conductor, a 
process put in use by Joseph Swan and Thomas Alva 
Edison developed the incandescent light bulb (78). 
Nowadays, electricity has proliferated all around the 
world, because of its increased efficiency and reduced 
costs. As a result, in the current modern life, homes and 
work places lack the complete dark nights, indeed, 2/3 of 
the population in Europe usually experience nights 
brighter than under a full moon (79). In addition to all, sine 
the 1960s, artificial lighting has improved to higher 
intensities, and they mainly contain short wave length 
light, correspondent to blue light. The exact wave length 
which is able to activate melanopsin, and hence alter the 
natural circadian cycle, leading to some serious 
pathophysiological consequences (77).   
Although light has proven benefits, and melanopsin 
activation by the blue component of either artificial or 
sunlight is crucial for the whole circadian system, 
however, studies has shown that timing is very important, 
and light at night, leading to melanopsin activation and, as 
a consequence, melatonin suppression, is harmful in many 
levels. The first evidence of the damaging effect the 
circadian disruption has, is demonstrated with jet lag; a 
condition resulted from rapid travel across multiple time 
zones, resulting in rhythm desynchronization, depressed 
mood, gastrointestinal complaints and cardiovascular 
problems (80). Another relevant condition is shift work, a 
condition affecting around 20% of workers in Europe and 
the US. Epidemiological studies linked shift-workers to 
increased risk of developing breast, prostate, colorectal, 
and endometrial cancers (81-83). All studies highlighting 
the problem of chronodisruption because of the exposure 
to artificial light at night resulting in melatonin 
suppression (77). From the other hand, Can some ocular 
diseases affect the expression of melanopsin? Hence, can it 
affect our ability to synchronize the circadian rhythm? 
Interesting studies indicated that melanopsin is among 
the first developing photosensitive cells in the mammalian 
retina (84), moreover, experiments in mice has proven 
their ability to detect light during embryonic stages (85). 
However, although they develop first, they have a longer 
period of proliferation and may be some of the last retinal 
neurons to die in the course of an organism’s lifetime. 
They are considered atypical central nervous system 
neurons, acting both as photoreceptors responding directly 
to environmental stimuli, as well as standard neurons 
integrating synaptic input and generating action potentials 
(86-88). Many studies have raised awareness towards these 
cells being resistant or less vulnerable to damage and 
disease compared to conventional RGCs. For instance, 
studies in some rodent glaucoma model examined the 
sparing of ipRGCs, suggesting that IOP threshold to 
damage these cells is much higher than it is in 
conventional RGCs (86). Different studies indicate 
melanopsin resistance to damage in optic nerve damage in 
inherited optic neuropathy, as well as studies indicating 
that these cells may be resistant to glutamate-induced 
excitotoxicity (87-90). Little is known about the cellular 
and molecular mechanisms that provide neuroprotection to 
these RGCs, however, it appears that along the 
development of glaucoma, melanopsin cells come to their 
fate. Different studies showed that melanopsin expressing 
ganglion cells deteriorated with ocular diseases, resulting 
in unfavorable outcomes, for example, a study to evaluate 
melanopsin response in patients with retinitis pigmentosa 
showed that blue light had a better effect over pupillary 
response in comparison to red light, however, the effect of 
short wave length was proportional to the ERG 
abnormality; patients with non-recordable ERG had 
significantly reduced response to melanopsin mediated 
effect “blue light” (91). Another study of melanopsin 
function in patients with glaucoma demonstrated that 
melanopsin could be used as an indicator of the 
progression of this disease, based on clinical evidence that 
showed that subjects with moderate and severe glaucoma 
had dysfunctional melanopsin mediated pupillary response 
in comparison to patients with early stage glaucoma (92). 
This study supports the facts that melanopsin containing 
retinal ganglion cells are more resisting to stress during the 
development of ocular pathologies, moreover, suggesting 
it as a biomarker to follow up the progressive deterioration 
noted in glaucoma patients.  
3.2. Light, melanopsin, and melatonin: possible 
therapeutical approach  
Very recently, an article published by Jesús Pintor was 
introducing the concept of pharmacology without drugs 
(93). In this article, the scientist made the following 
statement: “ Receptor-drug interaction is necessary to 
obtain a given effect; nevertheless, in some cases, instead 
of using a chemical messenger or drug it is possible to play 
with something that surrounds us: light”. In fact, the blue 
component of light is the specific agonist for melanopsin 
receptor, hence, stimulating or inhibiting this receptor 
could be achieved by means of switching the lights off 
and/or.  This suggestion is based on some published 
evidence, for instance, in vivo experiments on New 
Zealand white rabbits showed that light triggered ATP 
release in the aqueous humor (94). As the crystalline lens 
is the richest structure in ATP compared to the whole 
body, it have an important role in the lens by keeping all 
the active transporters working besides its protective effect 
Hanan Awad Alkozi 
@Real Academia Nacional de Farmacia. Spain 56 
over the retina by absorbing the harmful UV light (95). 
Also, ATP release in the aqueous humor would activate 
P2X receptors in the ciliary body which leads to IOP 
decrease; in other words, this could be a method of 
controlling IOP (96). Another study supporting this 
suggestion was mentioned previously (for more details, see 
section 2.), where crystalline lens cells responded variably 
under different light conditions in terms of melatonin 
synthesis, another important natural component in 
regulating IOP (70).  
Another striking fact about melanopsin in the retinal 
ganglion cells is that light conditions not only regulate its 
response, but also it regulates melanopsin expression itself. 
Experiments showed that melanopsin, in addition of being 
a key participant in photo-entrainment, its expression is 
also controlled by light conditions, and it increases 
significantly at night (97). The mechanism and functional 
implication of the changes of melanopsin expression are 
still unclear, however, this could explain the higher 
sensitivity children face when they suffer light at night, 
based on a study showed that melatonin suppression in 
children is more sensitive that adults due to light at night 
(98).  
As new discoveries are emerging since the discovery of 
melanopsin, the mutual relationship between both 
melanopsin and melatonin in the control of ocular 
physiology is becoming obvious., though more studies are 
necessary. Indications propose that melatonin may directly 
modulate the activity of melanopsin containing retinal 
ganglion cells as these cells express melatonin receptors 
(99), however most studies are speculative and the actual 
answer is still unclear.  
4.  CONCLUSION 
Melatonin and melanopsin tight bond is out of doubts, 
and light could become a new era of ocular pharmacology. 
In this sense, the current review highlighted the most 
recent discoveries in the eye and ocular pathologies with a 
special interest over glaucoma disease, being the second 
leading cause of blindness and giving its complexity in 
term of the effect of aqueous humor dynamics leading to 
retinal cells death and the positive effect of melatonin over 
regulating IOP. Melanopsin presence and activation is 
crucial during the day to favor melatonin production at 
night, however, modern life and artificial light are an 
important factor for harmony between both melatonin and 
melanopsin. 
Abreviations:   
IOP: Intraocular Pressure. 
AANAT: Aralalkymine N-acetyltransferase. 
NAS: N-acetylserotonin. 
HIOMT: Hydroxyindole O-methyltransferase. 
MT1-2: Melatonin receptor 1, 2 
NQO2: Quinone reductase 2. 
AC: Adenylate cyclase. 
cAMP: Cyclic adenosine mono- phosphate 
PKA: Protein kinase A. 
PLC: Phospholipase C. 
GC: guanylate cyclase. 
TRP: Transient Receptor Potential Ion Channels. 
TRPV4: Transient Receptor Potential vanilloid Channel 4.  
ipRGC: Intrinsically photosensitive retinal ganglion cells.  
PI(4,5)P2: Phosphatidylinositol 4,5-bisphosphate. 
IP3: Inositol 1,4,5-triphosphate 
DAG: Diacylglycerol. 
SCN: Suprachiasmatic nucleus. 
ERG: Electroretinogram. 
ATP: Adenisine triphosphate 
UV: Ultraviolet 
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